Related Experiment Video
Updated: May 26, 2026
13:18
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
PPAR gamma, bioactive lipids, and cancer progression.
Gregory T Robbins1, Daotai Nie
1Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine.
Frontiers in Bioscience (Landmark Edition)
|December 29, 2011
Summary
PPARgamma agonists show limited success as monotherapy for cancer but hold promise in combination treatments. PPARgamma protein levels are emerging as key prognostic and predictive markers for cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Peroxisome proliferator-activated receptor gamma (PPARgamma) has been extensively studied in tumor biology for over a decade.
- Research has primarily focused on PPARgamma agonists for cancer treatment, with varied outcomes.
Purpose of the Study:
- To review the evolution of cancer research concerning PPARgamma, including its mechanisms, target genes, and clinical applications.
- To evaluate the role of PPARgamma agonists, its tumor suppressor functions, and its impact on cancer stem cell differentiation.
Main Methods:
- Review of existing literature on PPARgamma in cancer research.
- Analysis of clinical trial data and preclinical studies (in vitro and animal models).
- Examination of studies on PPARgamma mutations and protein levels in cancer patients.
Main Results:
- PPARgamma agonists have shown limited efficacy as monotherapy in clinical trials.
- Combination treatments involving PPARgamma agonists demonstrate promise in preclinical models.
- PPARgamma's role as a tumor suppressor and inducer of cancer stem cell differentiation is under investigation.
- PPARgamma protein levels are identified as significant prognostic markers.
Conclusions:
- While PPARgamma agonists have not proven effective as standalone cancer treatments, they show potential in combination therapies.
- PPARgamma protein levels are valuable prognostic indicators and may serve as predictive markers for personalized cancer treatment strategies.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:26Signal Transduction: Overview
Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
Typically, signal transduction involves three...